{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:19:13Z","timestamp":1794557953345,"version":"4.9.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R42 AI106375"],"award-info":[{"award-number":["R42 AI106375"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI1117211"],"award-info":[{"award-number":["AI1117211"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21 AI127954"],"award-info":[{"award-number":["R21 AI127954"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI130060"],"award-info":[{"award-number":["R01 AI130060"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.amjmed.2021.10.007","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T06:47:30Z","timestamp":1635317250000},"page":"369-379.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":157,"title":["Oral Is the New IV. Challenging Decades of Blood and Bone Infection Dogma: A Systematic Review"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8782-5395","authenticated-orcid":false,"given":"Noah","family":"Wald-Dickler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Holtom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-5137","authenticated-orcid":false,"given":"Robert M.","family":"Centor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9701-8156","authenticated-orcid":false,"given":"Rachael. A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Baden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3632-1709","authenticated-orcid":false,"given":"Brad","family":"Spellberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2021.10.007_bib0001","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/cir842","article-title":"Systemic antibiotic therapy for chronic osteomyelitis in adults","volume":"54","author":"Spellberg","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0002","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jamainternmed.2020.0555","article-title":"Evaluation of a paradigm shift from intravenous antibiotics to oral step-down therapy for the treatment of infective endocarditis: a narrative review","volume":"180","author":"Spellberg","year":"2020","journal-title":"JAMA Inter Med"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0003","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1056\/NEJM197001222820406","article-title":"Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects","volume":"282","author":"Waldvogel","year":"1970","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0004","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJM195403112501005","article-title":"Treatment of bacterial endocarditis","volume":"250","author":"Finland","year":"1954","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0005","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1056\/NEJM195403042500906","article-title":"Treatment of bacterial endocarditis","volume":"250","author":"Finland","year":"1954","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0006","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/jrsm.1260","article-title":"Introduction, comparison, and validation of Meta-Essentials: a free and simple tool for meta-analysis","volume":"8","author":"Suurmond","year":"2017","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0007","doi-asserted-by":"crossref","first-page":"h2219","DOI":"10.1136\/bmj.h2219","article-title":"Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by methicillin resistant Staphylococcus aureus: randomised controlled trial","volume":"350","author":"Paul","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0008","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00006454-199306000-00003","article-title":"Antimicrobial treatment of occult bacteremia: a multicenter cooperative study","volume":"12","author":"Bass","year":"1993","journal-title":"Pediatr infect Dis J"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0009","doi-asserted-by":"crossref","first-page":"164S","DOI":"10.1016\/0002-9343(89)90050-8","article-title":"Intravenous\/oral ciprofloxacin versus ceftazidime in the treatment of serious infections","volume":"87","author":"Fass","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0010","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/0002-9343(91)90181-V","article-title":"Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics","volume":"91","author":"Paladino","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0011","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/jac\/44.6.799","article-title":"Levofloxacin in the empirical treatment of patients with suspected bacteraemia\/sepsis: comparison with imipenem\/cilastatin in an open, randomized trial","volume":"44","author":"Geddes","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0012","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1001\/archinte.159.1.53","article-title":"Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial","volume":"159","author":"Mombelli","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0013","doi-asserted-by":"crossref","first-page":"185S","DOI":"10.1016\/0002-9343(89)90055-7","article-title":"Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections","volume":"87","author":"Peacock","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0014","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1086\/424506","article-title":"A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection","volume":"39","author":"Schrenzel","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0015","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0016","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2106\/00004623-199072010-00017","article-title":"Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults","volume":"72","author":"Mader","year":"1990","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0017","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1128\/AAC.34.1.40","article-title":"Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis","volume":"34","author":"Gentry","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0018","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1128\/AAC.01504-08","article-title":"Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis","volume":"53","author":"Euba","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0019","first-page":"266","article-title":"Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis","volume":"82","author":"Greenberg","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0020","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1128\/AAC.35.3.538","article-title":"Ofloxacin versus parenteral therapy for chronic osteomyelitis","volume":"35","author":"Gentry","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0021","first-page":"244","article-title":"Oral ofloxacin versus parenteral imipenem-cilastatin in the treatment of osteomyelitis","volume":"12","author":"Gomis","year":"1999","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0022","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/cid\/ciy559","article-title":"Osteomyelitis complicating sacral pressure ulcers: Whether or not to treat with antibiotic therapy","volume":"68","author":"Wong","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0023","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/clind\/24.4.643","article-title":"Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens","volume":"24","author":"Lipsky","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0024","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1086\/380449","article-title":"Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam\/amoxicillin-clavulanate","volume":"38","author":"Lipsky","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0025","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2337\/dc13-1526","article-title":"Antibiotics versus conservative surgery for treating diabetic foot osteomyelitis: a randomized comparative trial","volume":"37","author":"Lazaro-Martinez","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0026","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2337\/dc14-1514","article-title":"Six-week versus twelve-week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: a multicenter open-label controlled randomized study","volume":"38","author":"Tone","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0027","doi-asserted-by":"crossref","first-page":"e1539","DOI":"10.1093\/cid\/ciaa1758","article-title":"Three versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: a prospective, randomized, non-inferiority pilot trial","volume":"73","author":"Gariani","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0028","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijantimicag.2016.05.021","article-title":"Short- versus long-duration levofloxacin plus rifampicin for acute staphylococcal prosthetic joint infection managed with implant retention: a randomised clinical trial","volume":"48","author":"Lora-Tamayo","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0029","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1093\/jac\/dkz202","article-title":"Four versus six weeks of antibiotic therapy for osteoarticular infections after implant removal: a randomized trial","volume":"74","author":"Benkabouche","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0030","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa2020198","article-title":"Antibiotic therapy for 6 or 12 weeks for prosthetic joint infection","volume":"384","author":"Bernard","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0031","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(14)61233-2","article-title":"Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial","volume":"385","author":"Bernard","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0032","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/106002809603000605","article-title":"Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis","volume":"30","author":"Amodio-Groton","year":"1996","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0033","doi-asserted-by":"crossref","first-page":"e843","DOI":"10.1016\/j.ijid.2012.07.009","article-title":"A prospective, randomized, double dummy, placebo-controlled trial of oral cefditoren pivoxil 400mg once daily as switch therapy after intravenous ceftriaxone in the treatment of acute pyelonephritis","volume":"16","author":"Monmaturapoj","year":"2012","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0034","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1080\/0036554021000026933","article-title":"Linezolid versus ceftriaxone\/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia","volume":"34","author":"San Pedro","year":"2002","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0035","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1097\/01.inf.0000086956.45566.55","article-title":"Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens","volume":"22","author":"Jantausch","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0036","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/01.inf.0000078160.29072.42","article-title":"Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children","volume":"22","author":"Kaplan","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0037","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/jac\/dkh088","article-title":"Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections","volume":"53","author":"Wilcox","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0038","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1086\/595686","article-title":"Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study","volume":"48","author":"Wilcox","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0039","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1007\/s10620-014-3233-0","article-title":"Early oral antibiotic switch compared with conventional intravenous antibiotic therapy for acute cholangitis with bacteremia","volume":"59","author":"Park","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0040","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1097\/01.inf.0000086955.93702.c7","article-title":"Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates","volume":"22","author":"Deville","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0041","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis","volume":"380","author":"Iversen","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0042","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijantimicag.2019.06.006","article-title":"High dose trimethoprim-sulfamethoxazole and clindamycin for Staphylococcus aureus endocarditis","volume":"54","author":"Tissot-Dupont","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0043","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJMc1902096","article-title":"Long-term outcomes of partial oral treatment of endocarditis","volume":"380","author":"Bundgaard","year":"2019","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.amjmed.2021.10.007_bib0044","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1093\/clinids\/13.Supplement_2.S160","article-title":"Antibiotic management of outpatients with endocarditis due to penicillin-susceptible streptococci","volume":"13","author":"Stamboulian","year":"1991","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0045","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0002-9343(96)00070-8","article-title":"Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy","volume":"101","author":"Heldman","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0046","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/jama.279.19.1537","article-title":"Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group","volume":"279","author":"Zimmerli","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0047","series-title":"FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients","year":"2018"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0048","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216029","article-title":"Fluoroquinolone-related adverse events resulting in health service use and costs: a systematic review","volume":"14","author":"Kuula","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0049","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/00007611-198202000-00005","article-title":"Clindamycin versus nafcillin or methicillin in the treatment of Staphylococcus aureus osteomyelitis in children","volume":"75","author":"Kaplan","year":"1982","journal-title":"South Med J"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0050","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/00006454-200206000-00010","article-title":"Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children","volume":"21","author":"Frank","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0051","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1542\/peds.99.6.846","article-title":"Simplified treatment of acute staphylococcal osteomyelitis of childhood. The Finnish Study Group","volume":"99","author":"Peltola","year":"1997","journal-title":"Pediatrics"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0052","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1469-0691.2011.03643.x","article-title":"Clindamycin vs. first-generation cephalosporins for acute osteoarticular infections of childhood\u2013a prospective quasi-randomized controlled trial","volume":"18","author":"Peltola","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0053","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s12879-017-2429-2","article-title":"Clindamycin-rifampin combination therapy for staphylococcal periprosthetic joint infections: a retrospective observational study","volume":"17","author":"Leijtens","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0054","doi-asserted-by":"crossref","first-page":"390","DOI":"10.7326\/0003-4819-117-5-390","article-title":"Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection","volume":"117","author":"Markowitz","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0055","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/cid\/ciy1134","article-title":"Short course antibiotic therapy-replacing Constantine units with \u201cshorter is better\u201d","volume":"69","author":"Wald-Dickler","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0056","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jamainternmed.2016.3646","article-title":"The new antibiotic mantra-\"shorter is better\"","volume":"176","author":"Spellberg","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0057","doi-asserted-by":"crossref","first-page":"210","DOI":"10.7326\/M19-1509","article-title":"Duration of antibiotic therapy: shorter is better","volume":"171","author":"Spellberg","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0058","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/cid\/ciy1054","article-title":"Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial","volume":"69","author":"Yahav","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0059","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1001\/jama.2020.6348","article-title":"Effect of C-reactive protein-guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteremia: a randomized clinical trial","volume":"323","author":"von Dach","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2021.10.007_bib0060","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/cid\/civ308","article-title":"Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals","volume":"61","author":"McDanel","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.amjmed.2021.10.007_bib0061","article-title":"Effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a systematic review and meta-analysis","volume":"2","author":"Mitaka","year":"2019","journal-title":"J Sci Innov Med"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934321006999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934321006999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:26:31Z","timestamp":1757582791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934321006999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0002934321006999"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2021.10.007","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Is the New IV. Challenging Decades of Blood and Bone Infection Dogma: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2021.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}